Sreemol Gokuladhas

Dr. Sreemol Gokuladhas

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
TFTayaza Fadason
Tayaza Fadason
SFSophie Farrow
Sophie Farrow
Sreemol GokuladhasSreemol Gokuladhas
Sreemol Gokuladhas
EGEvgeniia Golovina
Evgeniia Golovina
DNDenis Nyaga
Denis Nyaga
William SchierdingWilliam Schierding
William Schierding

30 January 2022 in Brain
Verified
Journal Article
Open access
PDF file
SFSophie L Farrow
Sophie L Farrow
William SchierdingWilliam Schierding
William Schierding
Sreemol GokuladhasSreemol Gokuladhas
Sreemol Gokuladhas
EGEvgeniia Golovina
Evgeniia Golovina
TFTayaza Fadason
Tayaza Fadason
Justin Martin O'sullivanJustin Martin O'sullivan
Justin Martin O'sullivan
The latest meta-analysis of genome-wide association studies identified 90 independent variants across 78 genomic regions associated with Parkinson’s disease, yet the mechanisms by which these variants influence the development of the disease remains largely elusive. To establish the functional gene regulatory networks associated with Parkinson’s disease risk variants, we utilized an approach combining spatial (chromosomal conformation capture) and functional (expression quantitative trait loci) data. We identified 518 genes subject to regulation by 76 Parkinson’s variants across 49 tissues, whicih encompass 36 peripheral and 13 CNS tissues. Notably, one-third of these genes were regulated via trans-acting mechanisms (distal; risk locus-gene separated by >1 Mb, or on different chromosomes). Of particular interest is the identification of a novel trans-expression quantitative trait loci–gene connection between rs10847864 and SYNJ1 in the adult brain cortex, highlighting a convergence between familial studies and Parkinson’s disease genome-wide association studies loci for SYNJ1 (PARK20) for the first time. Furthermore, we identified 16 neurodevelopment-specific expression quantitative trait loci–gene regulatory connections within the foetal cortex, consistent with hypotheses suggesting a neurodevelopmental involvement in the pathogenesis of Parkinson’s disease. Through utilizing Louvain clustering we extracted nine significant and highly intraconnected clusters within the entire gene regulatory network. The nine clusters are enriched for specific biological processes and pathways, some of which have not previously been associated with Parkinson’s disease. Together, our results not only contribute to an overall understanding of the mechanisms and impact of specific combinations of Parkinson’s disease variants, but also highlight the potential impact gene regulatory networks may have when elucidating aetiological subtypes of Parkinson’s disease.

27 February 2024 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
SFSophie L. Farrow
Sophie L. Farrow
Sreemol GokuladhasSreemol Gokuladhas
Sreemol Gokuladhas
William SchierdingWilliam Schierding
William Schierding
MPMichael Pudjihartono
Michael Pudjihartono
JPJo K. Perry
Jo K. Perry
Justin Martin O'sullivanJustin Martin O'sullivan
Justin Martin O'sullivan
Genome wide association studies (GWAS) have identified a number of genomic loci that are associated with Parkinson’s disease (PD) risk. However, the majority of these variants lie in non-coding regions, and thus the mechanisms by which they influence disease development, and/or potential subtypes, remain largely elusive. To address this, we used a massively parallel reporter assay (MPRA) to screen the regulatory function of 5254 variants that have a known or putative connection to PD. We identified 138 loci with enhancer activity, of which 27 exhibited allele-specific regulatory activity in HEK293 cells. The identified regulatory variant(s) typically did not match the original tag variant within the PD associated locus, supporting the need for deeper exploration of these loci. The existence of allele specific transcriptional impacts within HEK293 cells, confirms that at least a subset of the PD associated regions mark functional gene regulatory elements. Future functional studies that confirm the putative targets of the empirically verified regulatory variants will be crucial for gaining a greater understanding of how gene regulatory network(s) modulate PD risk.

23 January 2024 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
Sreemol GokuladhasSreemol Gokuladhas
Sreemol Gokuladhas
TFTayaza Fadason
Tayaza Fadason
SFSophie Farrow
Sophie Farrow
ACAntony Cooper
Antony Cooper
Justin Martin O'sullivanJustin Martin O'sullivan
Justin Martin O'sullivan
Understanding the biological mechanisms that underlie the non-motor symptoms of Parkinson’s disease (PD) requires comprehensive frameworks that unravel the complex interplay of genetic risk factors. Here, we used a disease-agnostic brain cortex gene regulatory network integrated with Mendelian Randomization analyses that identified 19 genes whose changes in expression were causally linked to PD. We further used the network to identify genes that are regulated by PD-associated genome-wide association study (GWAS) SNPs. Extended protein interaction networks derived from PD-risk genes and PD-associated SNPs identified convergent impacts on biological pathways and phenotypes, connecting PD with established co-occurring traits, including non-motor symptoms. These findings hold promise for therapeutic development. In conclusion, while distinct sets of genes likely influence PD risk and outcomes, the existence of genes in common and intersecting pathways associated with other traits suggests that they may contribute to both increased PD risk and symptom heterogeneity observed in people with Parkinson’s.

15 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
TFTayaza Fadason
Tayaza Fadason
Sreemol GokuladhasSreemol Gokuladhas
Sreemol Gokuladhas
EGEvgeniia Golovina
Evgeniia Golovina
DHDaniel Ho
Daniel Ho
SFSophie Farrow
Sophie Farrow
Justin Martin O'sullivanJustin Martin O'sullivan
Justin Martin O'sullivan
Introduction: A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was recently identified as the pathogen responsible for the COVID-19 outbreak. SARS-CoV-2 triggers severe pneumonia, which leads to acute respiratory distress syndrome and death in severe cases. As reported, SARS-CoV-2 is 80% genetically identical to the 2003 SARS-CoV virus. Angiotensin-converting enzyme 2 (ACE2) has been identified as the main receptor for entry of both SARS-CoV and SARS-CoV-2 into human cells. ACE2 is normally expressed in cardiovascular and lung type II alveolar epithelial cells, where it positively modulates the RAS system that regulates blood flow, pressure, and fluid homeostasis. Thus, virus-induced reduction of ACE2 gene expression is considered to make a significant contribution to severe acute respiratory failure. Chromatin remodeling plays a significant role in the regulation of ACE2 gene expression and the activity of regulatory elements within the genome. Methods: Here, we integrated data on physical chromatin interactions within the genome organization (captured by Hi-C) with tissue-specific gene expression data to identify spatial expression quantitative trait loci (eQTLs) and thus regulatory elements located within the ACE2 gene. Results: We identified regulatory elements within ACE2 that control the expression of PIR, CA5B, and VPS13C in the lung. The gene products of these genes are involved in inflammatory responses, de novo pyrimidine and polyamine synthesis, and the endoplasmic reticulum, respectively. Conclusion: Our study, although limited by the fact that the identification of the regulatory interactions is putative until proven by targeted experiments, supports the hypothesis that viral silencing of ACE2 alters the activity of gene regulatory regions and promotes an intra-cellular environment suitable for viral replication.

24 April 2020 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
Sreemol GokuladhasSreemol Gokuladhas
Sreemol Gokuladhas
William SchierdingWilliam Schierding
William Schierding
David Cameron-SmithDavid Cameron-Smith
David Cameron-Smith
MWMelissa Anne Wake
Melissa Anne Wake
ESEmma L. Scotter
Emma L. Scotter
Justin Martin O'sullivanJustin Martin O'sullivan
Justin Martin O'sullivan
Muscle weakness is a common consequence of both aging (sarcopenia) and neuromuscular disorders (NMD). Whilst genome-wide association (GWA) studies have identified genetic variants associated with grip strength (GS; measure of muscle strength/weakness) and NMDs, including multiple sclerosis (MS), myasthenia gravis (MG) and amyotrophic lateral sclerosis (ALS), it is not known whether there are common mechanisms between these phenotypes. To examine this, we have integrated GS and NMD associated genetic variants (single nucleotide polymorphisms; SNPs) in a multimorbid analysis that leverages high-throughput chromatin interaction (Hi-C) data and expression quantitative trait loci data to identify target genes (i.e., SNP-mediated gene regulation). Biological pathways enriched by these genes were then identified using next-generation pathway enrichment analysis. Lastly, druggable genes were identified using drug gene interaction (DGI) database. We identified gene regulatory mechanisms associated with GS, MG, MS, and ALS. The SNPs associated with GS regulate a subset of genes that are also regulated by the SNPs of MS, MG, and ALS. Yet, we did not find any genes commonly regulated by all four phenotype associated SNPs. By contrast, we identified significant enrichment in three pathways (mTOR signaling, axon guidance, and alcoholism) that are commonly affected by the gene regulatory mechanisms associated with all four phenotypes. 13% of the genes we identified were known drug targets, and GS shares at least one druggable gene and pathway with each of the NMD phenotypes. We have identified significant biological overlaps between GS and NMD, demonstrating the potential for spatial genetic analysis to identify common mechanisms between potential multimorbid phenotypes. Collectively, our results form the foundation for a shift from a gene to a pathway-based approach to the rationale design of therapeutic interventions and treatments for NMD.